Dissociating Autoantibody Responses against Ro52 Antigen in Patients with Anti-Synthetase or Anti-MDA5 Antibodies

Area of Science:

• Rheumatology
• Immunology
• Autoimmunity

Background:

• Autoantibodies against Ro52 protein are implicated in various autoimmune diseases.
• Distinguishing specific anti-Ro52 autoantibody profiles may refine disease classification.
• Patients with anti-synthetase or anti-melanoma differentiation-associated gene 5 (MDA5) antibodies represent distinct myositis subgroups.

Purpose of the Study:

• To investigate the clinical significance of dissociating anti-Ro52 autoantibody responses in patients with anti-synthetase or anti-MDA5 antibodies.
• To explore the role of "isolated anti-Ro52" and "anti-SSA-Ro52" patterns in disease subclassification.
• To determine if specific anti-Ro52 autoantibody profiles correlate with distinct clinical features and outcomes.

Main Methods:

• Prospective, single-center myositis cohort study.
• Analysis of 122 patients with anti-synthetase antibodies (RNA immunoprecipitation) and 34 with anti-MDA5 antibodies (enzyme immunoassay).
• Measurement of anti-Ro52 and anti-Ro/SSA antibodies using commercial enzyme immunoassay and RNA immunoprecipitation, respectively.

Main Results:

• Isolated anti-Ro52 positivity was prevalent in both anti-synthetase (32.8%) and anti-MDA5 (23.5%) antibody groups.
• In anti-synthetase patients, isolated anti-Ro52 or anti-SSA-Ro52 positivity correlated with Gottron's sign.
• In anti-MDA5 patients, isolated anti-Ro52 positivity was linked to initial respiratory insufficiency and poorer survival.

Conclusions:

• Isolated anti-Ro52 positivity may serve as a potential biomarker for stratifying patients with anti-synthetase and anti-MDA5 antibodies.
• The distinct autoantibody response against Ro52 warrants further investigation for its role in myositis subclassification.
• The clinical utility of differentiating isolated anti-Ro52 from overall anti-Ro52 positivity requires further elucidation.